Diogo Martins Branco: Inspiring session about Tumour Agnostic drug development ESMO Rare Cancers 2025
Diogo Martins Branco, Medical Oncologist at ESMO, shared a post on LinkedIn:
“Inspiring session about Tumour Agnostic drug development this morning at ESMO Rare Cancers 2025.
Benedikt Westphalen, our ESMO – European Society for Medical Oncology Precision Oncology Task Force Chair, pinpointing the potential role of The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S) on the roadmap of drug development.
Delighted to note the momentum of innovative Precision Oncology and high-quality Real Word Data coming together as a solution for generating confirmatory body of evidence for tumour-agnostic indications.
The ESMO – European Society for Medical Oncology is paving the path to improve the care of patients with rare cancers and common cancers with rare molecular alterations.”‘
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023